Altshuler David's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Nov 9, 2022
- Accession no.
- 0000899243-22-035443
- Filed
- Nov 9, 2022
- Trade date
- Nov 7, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $394.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Altshuler DavidCIK 0001550395 | Officer (EVP, Global Research and CSO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2022 | Common Stock | MOption exerciseAcquired | +1,303 | $187.53 | +$244,351.59 | 37,380 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −140 | $299.72F2,F3 | −$41,960.8 | 37,240 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −210 | $300.96F2,F4 | −$63,201.6 | 37,030 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −189 | $301.99F2,F5 | −$57,076.11 | 36,841 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −261 | $303.21F2,F6 | −$79,137.81 | 36,580 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −280 | $304.58F2,F7 | −$85,282.4 | 36,300 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −140 | $305.39F2,F8 | −$42,754.6 | 36,160 | Direct | |
| Nov 7, 2022 | Common Stock | SSaleDisposed | −83 | $306.57F2,F9 | −$25,445.31 | 36,077 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2022 | Common Stock | MOption exerciseDisposed | −1,303 | $0.00 | $0 | 1,304 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 7 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $299.72 (range $299.46 to $299.97).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $300.96 (range $300.54 to $301.18).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $301.99 (range $301.84 to $302.20).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $303.21 (range $302.89 to $303.45).
Referenced by the price of 1 transaction in Table I.
- F7
Open market sales reported on this line occurred at a weighted average price of $304.58 (range $304.14 to $304.91).
Referenced by the price of 1 transaction in Table I.
- F8
Open market sales reported on this line occurred at a weighted average price of $305.39 (range $305.38 to $305.39).
Referenced by the price of 1 transaction in Table I.
- F9
Open market sales reported on this line occurred at a weighted average price of $306.57 (range $306.45 to $307.22).
Referenced by the price of 1 transaction in Table I.